[Exploration of CAR-T cell combination therapy strategies in lymphoma].
作者信息
Zhang Y Q, Mei H, Hu Y
机构信息
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Oct 14;43(10):873-876. doi: 10.3760/cma.j.issn.0253-2727.2022.10.014.
Abstract
摘要
相似文献
1
[Exploration of CAR-T cell combination therapy strategies in lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2022 Oct 14;43(10):873-876. doi: 10.3760/cma.j.issn.0253-2727.2022.10.014.
2
Beyond CD19 CAR-T cells in lymphoma.
Curr Opin Immunol. 2022 Feb;74:46-52. doi: 10.1016/j.coi.2021.09.009. Epub 2021 Nov 17.
3
[Novel therapy for malignant lymphoma: adoptive immuno-gene therapy using chimeric antigen receptor(CAR)-expressing T lymphocytes].
Nihon Rinsho. 2014 Mar;72(3):547-52.
4
CAR T cell therapy: inroads to response and resistance.
Nat Rev Immunol. 2019 Feb;19(2):73-74. doi: 10.1038/s41577-018-0119-y.
5
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
BMJ Open. 2019 May 19;9(5):e026644. doi: 10.1136/bmjopen-2018-026644.
6
CAR T-Cell Therapy in Hematological Malignancies.
Int J Mol Sci. 2021 Aug 20;22(16):8996. doi: 10.3390/ijms22168996.
7
CAR T cell therapy becomes CHIC: "cytokine help intensified CAR" T cells.
Front Immunol. 2023 Jan 9;13:1090959. doi: 10.3389/fimmu.2022.1090959. eCollection 2022.
8
Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019.
Crit Rev Oncol Hematol. 2020 Aug;152:103007. doi: 10.1016/j.critrevonc.2020.103007. Epub 2020 May 29.
9
Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis.
Medicine (Baltimore). 2019 Oct;98(42):e17506. doi: 10.1097/MD.0000000000017506.
10
A review of chimeric antigen receptor T-cells in lymphoma.
Expert Rev Hematol. 2019 Jul;12(7):551-561. doi: 10.1080/17474086.2019.1629901. Epub 2019 Jun 19.
引用本文的文献
1
[The mechanisms and salvage treatment strategies underlying positive relapse following CD19 CAR-T cell therapy in B-acute lymphoblastic leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):970-976. doi: 10.3760/cma.j.cn121090-20240701-00242.
本文引用的文献
1
Upregulation of CD22 by Chidamide promotes CAR T cells functionality.
Sci Rep. 2021 Oct 19;11(1):20637. doi: 10.1038/s41598-021-00227-4.
2
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Blood. 2022 Feb 17;139(7):1026-1038. doi: 10.1182/blood.2021012634.
3
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Transplant Cell Ther. 2021 Nov;27(11):910.e1-910.e11. doi: 10.1016/j.jtct.2021.08.012. Epub 2021 Aug 20.
4
Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
J Hematol Oncol. 2021 Jul 21;14(1):113. doi: 10.1186/s13045-021-01117-y.
5
-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.
Front Immunol. 2021 May 25;12:599493. doi: 10.3389/fimmu.2021.599493. eCollection 2021.
6
A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
Clin Cancer Res. 2021 Jul 1;27(13):3757-3771. doi: 10.1158/1078-0432.CCR-20-2487. Epub 2021 Apr 2.
7
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.
Science. 2021 Apr 2;372(6537). doi: 10.1126/science.aba1786.
8
Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ CD4 T Cells Through Enhancing IκBα Degradation and NF-κB Activation.
Front Cell Dev Biol. 2021 Mar 15;9:647713. doi: 10.3389/fcell.2021.647713. eCollection 2021.
9
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.
Sci Transl Med. 2021 Jan 6;13(575). doi: 10.1126/scitranslmed.abb6295.
10
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Blood Adv. 2020 Jul 14;4(13):2871-2883. doi: 10.1182/bloodadvances.2020001837.
Zotero 插件